Furthermore, the correlation in HSCT patients of chemerin plasma levels and the number of circulating CMKLR1+ monocytes with the GvHD clinical outcome will provide precious clues to understand whether the CMKLR1/chemerin axis could be exploited as a new therapeutic target in HSCT patients experiencing severe GI GvHD. Here, CMKLR1 is linked to graft versus host disease.